73472-94-3

Basic information

• Product Name: 3-BroMo-2-hydroxy-propionic acid ethyl ester
• Synonyms: 3-BroMo-2-hydroxy-propionic acid ethyl ester;Ethyl 3-Bromo-2-(hydroxyimino)propanoate
• CAS NO: 73472-94-3
• Molecular Formula: C₅H₈BrNO₃
• Molecular Weight: 197.02716
• Mol File: 73472-94-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-BroMo-2-hydroxy-propionic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BroMo-2-hydroxy-propionic acid ethyl ester(73472-94-3)
• EPA Substance Registry System: 3-BroMo-2-hydroxy-propionic acid ethyl ester(73472-94-3)

Safety Data

• Hazardous Substances Data: 73472-94-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-2-hydroxy-propionic acid ethyl ester is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and properties contribute to the development of new drugs and medications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-2-hydroxy-propionic acid ethyl ester is employed as a reagent in the synthesis of agrochemicals. Its role in creating new compounds aids in the advancement of products for agricultural applications.
Used in Organic Synthesis:
3-Bromo-2-hydroxy-propionic acid ethyl ester is used as a reagent in organic synthesis for the production of a wide range of chemical compounds. Its versatility in chemical reactions makes it a valuable component in the synthesis process.

Upstream product

• 617-35-6 2-oxo-propionic acid ethyl ester 
• 64-17-5 ethanol 
• 1113-59-3 bromopyruvic acid 
• 70-23-5 ethyl Bromopyruvate 
• 5470-11-1 hydroxylamine hydrochloride 

Downstream Products

• 73473-16-2 6-methyl-6-phenyl-5,6-dihydro-4H-[1,2]oxazine-3-carboxylic acid 
• 73473-06-0 3-ethoxycarbonyl-6-methyl-6-phenyl-5,6-dihydro-4H-1,2-oxazine 
• 125173-15-1 6-Phenyl-6-trimethylsilanyloxy-5,6-dihydro-4H-[1,2]oxazine-3-carboxylic acid ethyl ester 
• 132868-26-9 5-Methyl-6-phenoxy-5,6-dihydro-4H-[1,2]oxazine-3-carboxylic acid ethyl ester 
• 134288-22-5 ethyl (S)-3-(4-(methyl(1-(((phenylmethyl)oxy)carbonyl)-2-methylpropyl)amino)-6,7-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylbenzo)-1H-indol-3-yl)-2-oximidopropionate 
• 142906-92-1 ethyl 2-hydroxyimino-3-<2-(3-phenylpropyl)indol-3-yl>propanoate 
• 142906-94-3 ethyl 2-hydroxyimino-3-<5-bromo-2-(3-phenylpropyl)indol-3-yl>propanoate 
• 142906-95-4 ethyl 2-hydroxyimino-3-<5-bromo-2-(4-phenylbutyl)indol-3-yl>propanoate 
• 87497-88-9 ethyl 2-nitrosopropenoate 
• 160255-57-2 (S)-2-[(3-{2-Ethoxycarbonyl-2-[(Z)-hydroxyimino]-ethyl}-1H-indol-4-yl)-methyl-amino]-3-methyl-butyric acid benzyl ester 
• 160096-23-1 (S)-2-[(3-{2-Ethoxycarbonyl-2-[(Z)-hydroxyimino]-ethyl}-7-octyl-1H-indol-4-yl)-methyl-amino]-3-methyl-butyric acid benzyl ester 
• 496808-11-8 ethyl (2S,3R,4R,5R)-4-(benzyloxy)-2,3-isopropylidenedioxy-1,6-dioxa-7-azaspiro[4.5]dec-7-ene-8-carboxylate 
• 188062-43-3 8-ethoxycarbonyl-7-deazaguanine 
• 124455-77-2 ethyl 1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxylate 

Relevant articles and documents

Synthesis of some novel tricyclic α-aminoacid esters and potential bioactive compounds via 1,2-prototropy and 1,3-APT cascade reactions

Some novel cyclic α-aminoacid esters and potential bioactive compounds were prepared via thermal 1,2-prototropy- and 1,3-APT oxime nitrone-1,3-dipolar cycloaddition cascades reactions. This substrate allows the influence of the new stereocentres on the cascade to be assessed with respect to the configuration of the nitrone that is generated and the facial selectivity of the subsequent cycloaddition.

Synthesis of some novel tricyclic α- amino acid esters and potential bioactive compounds via 1,2-prototropy and 1,3-APT cascade reactions

Some novel cyclic α-aminoacid esters and potential bioactive compounds were prepared via thermal 1,2-prototropy- and 1,3-APT oxime nitrone-1,3-dipolar cycloaddition cascades reactions. This substrate allows the influence of the new stereocentres on the cascade to be assessed with respect to the configuration of the nitrone that is generated and the facial selectivity of the subsequent cycloaddition.

Synthesis of sterically encumbered 11β-aminoprogesterone derivatives and evaluation as 11β-hydroxysteroid dehydrogenase inhibitors and mineralocorticoid receptor antagonists

11β-Hydroxyprogesterone is a well-known nonselective inhibitor of 11β-hydroxysteroid dehydrogenase (11βHSD) types 1 and 2. It also activates the mineralocorticoid receptor (MR). Modulation of corticosteroid action by inhibition of 11βHSDs or blocking MR i

Palladium-catalysed imidoylative spirocyclization of 3-(2-isocyanoethyl)indoles

A palladium-catalysed construction of spiroindolines through dearomative spirocyclization of 3-(2-isocyanoethyl)indoles has been developed. 2′-Aryl-, vinyl-, and alkyl-substituted spiroindolines could be accessed under mild conditions with excellent functional group tolerance. C1-tethered oxindole- and indole-spiroindoline bisheterocycles were generated in high yieldsviaalkene/allene insertion and an imidoylative spirocyclization cascade. Additionally, a tandem dearomatization of two different indoles was realized withN-(2-bromobenzoyl)indoles as the electrophilic coupling partner of 3-(2-isocyanoethyl)indoles, affording polyindoline-spiroindoline bisheterocyclic scaffolds conveniently. Under the catalysis of Pd(OAc)2and a spinol-derived phosphoramidite ligand, chiral spiroindolines were successfully accessed with up to 95% yield and 85% ee.

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Described herein are compounds having the following structure: formula (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof. Also disclosed are compositions containing the compounds, methods of inhibiting activity of DYRKl A in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

A method for synthesizing pyrroloquinoline quinone (by machine translation)

The invention relates to a synthetic pyrroloquinoline quinone of the method, the method to pyruvic acid ethyl ester as the starting synthetic raw material, preparation pyrroloquinoline quinone. In the synthetic method of the present invention, compound 4 synthesis of compound 5 is the key step in the synthetic route, in the key step 5) in, the invention creative use of hexafluoro antimonate ion liquid, hexafluoro titanate ion liquid, six fluorine niobium acid salt ion liquid such as Lewis acid ionic liquid, the ionic liquid has the function of the reaction medium and the catalyst, thereby improving the response speed and the yield of this step. In addition, the invention preferably use the [BMIm] SbF6 Ionic liquid, [BMIm] SbF6 Ionic liquid and Sc (OTf)3 Can be formed of a higher catalytic activity [Sc (OTf)3 -x ] [SbF6 ], Can make the reaction efficiency is greatly improved, and the obtained reaction product in [BMIm] SbF6 The solubility of the ionic liquid in small, easily precipitated, so as to improve the reaction yield (can be up to 96%). (by machine translation)

Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation

DYRK1A has been implicated as an important drug target in various therapeutic areas, including neurological disorders and oncology. DYRK1A has more recently been shown to be involved in pathways regulating human β-cell proliferation, thus making it a potential therapeutic target for both Type 1 and Type 2 diabetes. Our group, using a high-throughput phenotypic screen, identified harmine that is able to induce β-cell proliferation both in vitro and in vivo. Since harmine has suboptimal kinase selectivity, we sought to expand structure-activity relationships for harmine's DYRK1A activity, to enhance selectivity, while retaining human β-cell proliferation capability. We carried out the optimization of the 1-position of harmine and synthesized 15 harmine analogues. Six compounds showed excellent DYRK1A inhibition with IC50 in the range of 49.5-264 nM. Two compounds, 2-2 and 2-8, exhibited excellent human β-cell proliferation at doses of 3-30 μM, and compound 2-2 showed improved kinase selectivity as compared to harmine.

COMPOUNS, COMPOSITIONS AND METHODS OF USE

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

Compound as apoptosis protein inhibitor, and application thereof

The present invention belongs to the field of medical chemistry, relates to a class of compounds of apoptosis protein inhibitors, and applications thereof, and particularly provides a compound represented by a formula I, or an isomer thereof, a pharmaceut

Unnatural α-amino ethyl esters from diethyl malonate or ethyl β-bromo-α-hydroxyiminocarboxylate

We have explored here the scope of the age-old diethyl malonate-based accesses to α-amino esters involving Knoevenagel condensations of diethyl malonate on aldehydes, reductions of the resulting alkylidenemalonates, the preparation of the corresponding α-hydroxyimino esters and their final reduction. This synthetic pathway turned out to be general although some unexpected limitations were encountered. The synthetic modifications of some of the intermediates - using Suzuki-Miyaura coupling or cycloadditions - before undertaking the oximation step - provided accesses to further α-amino esters. Moreover, other pathways to α-hydroxyimino esters were explored including an attempt to improve the cycloadditions between ethyl β-bromo-α-hydroxyiminocarboxylate and various alkylfuranes.